Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in HIV-Associated Solid Tumors and Classical Hodgkin Lymphoma
NCT02408861Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2015
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of nivolumab and ipilimumab in solid tumor and classical Hodgkin lymphoma (cHL) (7 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Nivolumab at 6 weeks, Dose Limiting Toxicities at 6 weeks and 1 more. Started Oct 2015; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
solid tumorclassical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02408861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02408861.